Drug Discovery & Pharmaceuticals

RSS

Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026

Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows.

5 Feb 2026

New platform improves prediction of human antibody drug responses

An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how antibody medicines are tested and brought to patients. The

1 Feb 2026

Evosep launches IQ/OQ protocols for the Evosep Eno System at WCBP 2026

Evosep is proud to announce a major advancement in quality assurance for pharmaceutical and regulated laboratories with the introduction of Installation Qualification (IQ) and Operational Qualification (OQ) protocols for its Evosep Eno system.

From Evosep 30 Jan 2026

CDD European Life Science Community Meeting

Collaborative Drug Discovery's Community Meeting brings the European technology and scientific communities together.

From CDD Vault 30 Jan 2026

iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare diseases

iXCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud Biosciences, an innovator in organoid development and complex 3D biology, today announced a partnership to develop a personalized, human-based approach for predicting drug safety and informing translational decision-making in rare diseases.

27 Jan 2026

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

27 Jan 2026

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

From WuXi Biologics 27 Jan 2026

Proimmune introduces Mastering Immunity 2026 - Shanghai symposium to address key immunogenicity challenges

ProImmune Ltd, a global leader in immunological reagents and services, announced the launch of Mastering Immunity 2026 - Shanghai, an inaugural symposium in China providing practical, real-world guidance to help drug developers manage immunogenicity risk.

21 Jan 2026

Accelerating kinase drug discovery with validated kinase activity assay kits

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

From Eurofins Discovery 20 Jan 2026

Dr Adam Davenport appointed as CSO to strengthen leadership in integrated drug discovery

We are pleased to announce the appointment of Dr Adam Davenport as Chief Scientific Officer to spearhead our integrated drug discovery offering for biotech and pharmaceutical partners.

From Concept Life Sciences 19 Jan 2026

New chemistry revives neurokinin-1 receptor as depression treatment target

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder.

14 Jan 2026

Axol Bioscience raises $2.8 M to advance US expansion and product development

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 million) in funding.

13 Jan 2026

OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round.

12 Jan 2026

FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA

FairJourney Bio (FJBio), a leading global provider of antibody discovery and development services, today announced the expansion of its portfolio with the launch of state-of-the-art cryo-electron microscopy (cryo-EM) services, supported through the Company's advanced laboratories in San Diego, CA.

12 Jan 2026

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

Aston Sci. Inc., a clinical-stage biopharmaceutical company pioneering next-generation therapeutic cancer vaccines, announced today that it has implemented CDD Vault®, the secure, cloud-based research informatics platform from Collaborative Drug Discovery (CDD).

From CDD Vault 10 Jan 2026

UC Davis team creates new class of serotonin-effecting drugs

UC Davis researchers have developed a new method that uses light to transform amino acids - the building blocks of proteins - into molecules that are similar in structure to psychedelics and mimic their interaction with the brain.

8 Jan 2026

Weight loss drugs may cause nutritional deficiencies without proper guidance

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.

7 Jan 2026

Newly discovered molecule could be a game-changer in the fight against deadly fungi

Fungal infections kill millions of people each year, and modern medicine is struggling to keep up. But researchers at McMaster University have identified a molecule that may help turn the tide — butyrolactol A, a chemical compound that targets a deadly, disease-causing fungi called Cryptococcus neoformans.

7 Jan 2026

Nuclera eProtein Discovery System installed at leading universities in Taiwan

Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has completed the first installations of eProtein Discovery in Asia, with systems now operational at the Department of Pharmacy and the Department of Chemistry at the National Taiwan University (NTU) College of Medicine and the Center for Bioscience and Biotechnology and Department of Chemical Engineering at the National Cheng Kung University (NCKU).

7 Jan 2026

Enveda’s third asset to the clinic with US FDA IND clearance: What it means for Inflammatory Bowel Disease

Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, has announced that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ENV-6946.

From Hanson Wade Group - 4th Precision Medicine in Inflammatory Bowel Disease Summit 6 Jan 2026

Drug Discovery & Pharmaceuticals

Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026

New platform improves prediction of human antibody drug responses

Evosep launches IQ/OQ protocols for the Evosep Eno System at WCBP 2026

CDD European Life Science Community Meeting

iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare diseases

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

Proimmune introduces Mastering Immunity 2026 - Shanghai symposium to address key immunogenicity challenges

Accelerating kinase drug discovery with validated kinase activity assay kits

Dr Adam Davenport appointed as CSO to strengthen leadership in integrated drug discovery

New chemistry revives neurokinin-1 receptor as depression treatment target

Axol Bioscience raises $2.8 M to advance US expansion and product development

OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

UC Davis team creates new class of serotonin-effecting drugs

Weight loss drugs may cause nutritional deficiencies without proper guidance

Newly discovered molecule could be a game-changer in the fight against deadly fungi

Nuclera eProtein Discovery System installed at leading universities in Taiwan

Enveda’s third asset to the clinic with US FDA IND clearance: What it means for Inflammatory Bowel Disease

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest Life Science News